November 21, 2023 02:41 PM EST
R&D
FDA+
Manufacturing

FDA warns Cipla's al­buterol in­haler plant af­ter thou­sands of com­plaints

Zachary Brennan

Senior Editor

The FDA on Tues­day raised se­ri­ous ques­tions about In­di­an al­buterol in­haler man­u­fac­tur­er Cipla in a new warn­ing let­ter af­ter the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times